Prostatic Artery Embolization Using N-butyl Cyanoacrylate for Benign Prostatic Hyperplasia: A Two-center Prospective Study

For many aging men, a common and often frustrating condition arises when the prostate gland, a small organ situated just below the bladder, grows larger than it should be. This enlargement, known medically as benign prostatic hyperplasia, squeezes the tube that carries urine out of the body. The result is a collection of bothersome symptoms: a frequent and urgent need to urinate, a weak stream, or the feeling that the bladder never fully empties. While medications and surgery have long been the standard ways to manage these issues, a newer approach has emerged that avoids cutting or removing tissue. This method involves guiding a tiny catheter through the blood vessels to the arteries feeding the prostate and blocking the flow of blood to the overgrown tissue. Without its blood supply, the enlarged part of the gland shrinks, relieving pressure on the urinary tube. This procedure, called prostatic artery embolization, has been studied extensively using small solid particles to block the vessels, but researchers have been exploring whether liquid glue might work just as well, or perhaps even better, in certain situations.

In a recent two-center study conducted in Vietnam, a team of researchers set out to test this specific liquid approach on sixty-nine men suffering from symptomatic prostate enlargement. Instead of the solid particles typically used, they injected a liquid medical adhesive known as N-butyl-2-cyanoacrylate directly into the arteries supplying the prostate. This substance hardens quickly upon contact with blood, effectively sealing off the vessels and causing the targeted tissue to wither away. The researchers tracked the men's progress over a six-month period, measuring not just how their symptoms changed, but also how the size of their prostate, their blood markers, and their overall quality of life shifted. They also paid close attention to the technical details of the procedure, such as how long it took and how much radiation exposure the patients received, while keeping a careful watch for any side effects.

The results of the study were strikingly positive. Within three months of the procedure, the men reported a dramatic reduction in their urinary troubles. On a standard scale used to measure symptom severity, the average score dropped from a high of twenty-two at the start to just eight after three months, and it remained low at seven after six months. This improvement was not merely a feeling; it was backed by physical changes. The volume of the prostate gland decreased significantly, and the amount of urine left in the bladder after voiding also fell. Even the levels of a specific protein in the blood, often used as a marker for prostate health, showed a marked decline. The study found that nearly all of the patients, specifically ninety-seven percent, experienced what the researchers defined as a successful clinical outcome, meaning their symptoms were substantially relieved.

Safety was a major focus of the investigation, and the data showed that the procedure was well-tolerated. While more than half of the patients experienced some form of complication, the vast majority of these were minor and manageable, such as temporary pain or fever, rather than serious medical events. The researchers noted that the procedure itself was efficient, with manageable times for the doctors and acceptable levels of radiation exposure for the patients. The study concluded that using this liquid adhesive to embolize the prostatic arteries is a safe and effective way to treat benign prostatic hyperplasia. It offers a viable alternative to traditional methods, providing sustained relief from urinary symptoms and a significant reduction in prostate size without the need for invasive surgery.